UEMS Medical Specialty
Neurology & CNS — Page 2
Research covering the central and peripheral nervous system, blood–brain barrier (BBB) permeability, neuroinflammation, neurodegenerative diseases, and brain-targeted nutraceutical delivery systems.
40
dossiers
Catecholamine Homeostasis & Executive Function
Kava (Piper methysticum) in Psychiatry: Clinical Effects, Mechanisms, and Safety Signals with Emphasis on Anxiety Disorders
Developing safe and effective Kava-derived anxiolytics is challenging due to inherent hepatotoxicity concerns and potential herb-drug interactions, necessitating novel formulation strategies to mitigate adverse events while preserving therapeutic efficacy.
Catecholamine Homeostasis & Executive Function
Narcissistic Parenting and ADHD: Indirect Pathways and Diagnostic Implications
Precisely differentiating ADHD from trauma-related phenocopies in children of narcissistic parents presents a significant diagnostic hurdle, complicating targeted therapeutic development.
Precision Microbiome & Gut-Brain Axis
The Neuroimmune Continuum: Mechanisms, Paradigm Shifts, and Translational Frontiers in Psychoneuroimmunology
Translating complex psychoneuroimmunological mechanisms, including BBB permeability, specific cytokine pathways, and targeted microglial modulation, into stable and bioavailable therapeutic formulations presents a significant CDMO hurdle.
Post-GLP-1 Metabolic Optimization
Nutraceutical Toxicology and Herb-Drug Interactions (HDI/NDI): A Clinical Review of Six Critical Pharmacological Mechanisms
Developing safe and effective drug formulations requires comprehensive consideration of potential, often undisclosed, herb-drug interactions that can compromise efficacy or lead to life-threatening toxicities, especially with narrow therapeutic index compounds.
Precision Microbiome & Gut-Brain Axis
Pharmacomicrobiomics: Gut Microbiota Modulation of Drug Efficacy and Nutraceutical Biotransformation
Integrating the profound and variable metabolic capacity of the gut microbiome into pharmaceutical development to ensure consistent drug efficacy and bioavailability across diverse patient populations is a significant hurdle.
Catecholamine Homeostasis & Executive Function
Posttraumatic Stress Disorder, Complex PTSD, and Attention-Deficit/Hyperactivity Disorder: Comorbidity and Shared Mechanisms
The high comorbidity and overlapping symptomatology of PTSD, CPTSD, and ADHD present a key challenge. Developing precise therapies requires unraveling their complex, shared neurobiological mechanisms.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Quantum Theories of Consciousness in Psychiatry: The Orchestrated Objective Reduction (Orch-OR) Hypothesis
Developing therapeutic interventions that modulate consciousness or psychiatric pathology requires targeting quantum-level phenomena within neuronal microtubules, posing a significant challenge for conventional drug design and delivery given the elusive nature of these mechanisms.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Quantum Physics and Medicine: A Review of Common Aspects
Integrating quantum phenomena, essential for advanced diagnostics and computation, into stable and functional biomedical devices for precise clinical application amidst complex biological environments presents a significant CDMO hurdle.
Catecholamine Homeostasis & Executive Function
Quantum Physics and Psychiatry: Methodological and Metaphorical Parallels
Integrating the inherent subjectivity and observer-dependent dynamics described by quantum-psychiatry parallels into objective, reproducible clinical trial designs and drug development pathways for mental health remains a significant challenge for pharmaceutical R&D.
Cellular Longevity & Senolytics
Cellular Senescence, SASP, and Senolytic Targeting of Age-Related Pathologies
Delivering senolytics effectively to specific senescent cell populations and overcoming their multi-pathway pro-survival redundancy (SCAPs) without off-target effects remains a significant challenge for therapeutic development.
Catecholamine Homeostasis & Executive Function
Clinical Nutrigenomics: One-Carbon Metabolism, MTHFR/COMT Polymorphisms, and Unmetabolized Folic Acid Toxicity
Developing stable, bioavailable dosage forms of 5-methyltetrahydrofolate (5-MTHF) that effectively bypass common one-carbon metabolism genetic polymorphisms (e.g., MTHFR, COMT) is critical to prevent unmetabolized folic acid (UMFA) toxicity and ensure optimal folate status. This requires precise formulation to overcome stability issues inherent to reduced folates while ensuring clinical efficacy across genetically diverse populations.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Ketogenic Diet-Specified Interventions in Neurodegenerative Disease Mechanisms
Developing a formulation that achieves consistent and measurable ketosis while optimizing bioavailability and tolerability in neurodegenerative conditions is a key challenge.
Advanced BBB Permeability Solutions
Lipidic Nanoformulations for BBB Transport of Lipophilic Phytochemicals: Current Evidence and Challenges
Lipophilic phytochemicals exhibit poor systemic and brain bioavailability due to rapid metabolism, low solubility, and active efflux at the blood-brain barrier, impeding clinical translation.
Precision Microbiome & Gut-Brain Axis
Nutrition and Psychiatric Disorders: A Comprehensive Narrative Review of the Evidence Through 2026
Optimal dietary interventions for psychiatric disorders remain poorly standardized and show high variability in effectiveness.
Precision Microbiome & Gut-Brain Axis
Enteric Delivery of Butyrate: Overcoming Gastrointestinal Barriers for Vagal Activation
Free butyrate salts dissolve prematurely in the upper gastrointestinal tract, limiting their availability for distal gut signaling. Additionally, their pungent odor and taste present significant challenges for patient adherence in chronic applications.
Precision Microbiome & Gut-Brain Axis
Gut-Brain Axis in ADHD: Microbiota-Mediated Dopaminergic Pathway Modulation
Developing scientifically validated microbiome-targeted interventions for ADHD involves addressing the challenges of heterogeneity in clinical outcomes and identifying precise microbial mechanisms. Formulating stable, effective probiotics or synbiotics with demonstrated clinical benefits remains a major hurdle.
No dossiers match the selected MeSH topic in this page. Try another tag or clear the filter.
Custom Formulation Available
Need a Dossier Built Around Your Molecule?
Our R&D team will conduct a Paid Discovery Audit and build a proprietary clinical dossier for your specific active ingredient or therapeutic target. Full IP transfer included.